Background: The aim of this pilot randomized controlled trial was to test the feasibility of a computerized cognitive training targeting executive dysfunction in late-life depression and to investigate its impact on mood, cognition, and brain-derived neurotrophic factor (BDNF) levels.
Methods: A total of 28 community-living Chinese individuals aged 55-75 with moderate-to-severe depression and cognitive symptoms (but without mild cognitive impairment or dementia) were recruited from a community centre in Hong Kong. Participants were randomly allocated to either the experimental (receiving computerized cognitive training) or the control group (receiving computer-based health education). Both programs lasted for one hour and were conducted twice a week for 6 weeks at the community centre. We assessed mood using the Hamilton Rating Scale for Depression (HAM-D) and Patient Health Questionaire-9 (PHQ-9), cognition using the Montreal Cognitive Assessment (MoCA), and serum BDNF levels at baseline and follow-up. We performed repeated measures analysis of variance to compare the differences in outcome changes between groups and correlation analysis to test if changes in mood and cognition correlated with changes in BDNF level.
Results: Our sample had a mean age of 66.8 (SD = 5.3) years, a mean HAM-D score of 19.4 (SD = 7.5), and a mean PHQ-9 score of 18.0 (SD = 6.3). No adverse effects were reported. Significant differences were observed between the experimental and control groups in changes in HAM-D (-8.4 vs. -2.9; group difference = -5.5; = 0.01), PHQ-9 (-6.6 vs. -0.6; -6.0; < 0.001), MoCA (1.4 vs. -1.3; 2.7; = 0.001), and serum BDNF levels (in pg/ml; 2088.3 vs. -3277.4; 5365.6; = 0.02). Additionally, changes in HAM-D, PHQ-9, and MoCA scores correlated significantly with changes in BDNF level.
Conclusion: With computerized cognitive training improving mood and cognition and increasing serum BDNF levels in 6 weeks, it may serve as a safe and effective evidence-based alternative or adjuvant treatment for late-life depression.
Clinical Trial Registration: https://www.chictr.org.cn/indexEN.html, identifier ChiCTR1900027029.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827875 | PMC |
| http://dx.doi.org/10.3389/fpsyt.2023.1287822 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ABBA Letter Alternation: A telehealth inspired measure of executive functioning/inhibitory control.
Clin Neuropsychol
January 2025
Department of Neurology, Emory University School of Medicine, Emory University, Atlanta, GA, USA.
To introduce ABBA Letter Alternation (ABBA) as a computerized measure of response inhibition/response alternation developed for telehealth following restrictions of in-person testing due to COVID-19. ABBA consists of two PowerPoint-administered trials: Letter Reading of 25 capital As or Bs individually presented, and Letter Alternation with instructions to say the opposite letter to what is presented. We obtained initial normative ABBA performance from 899 healthy research volunteers participating in the Emory Healthy Brain Study (EHBS) with Montreal Cognitive Assessment (MoCA) scores 24/30 and higher.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China.
Background: The regulatory role of Trimethylamine-N-oxide (TMAO) for cognition from the perspective of microbiota-gut-brain (MGB) axis in AD remains unclear.
Method: In clinical cohort study for effects of 24-week computerized cognitive training (CCT), registered on clinicaltrials.gov (NCT06094452), plasma TMAO levels were quantified using ELISA in MCI (n=39) and mild AD patients (n=35).
Background: An easy and reliable method for detection of Alzheimer's Disease (AD) and mild cognitive impairment (MCI) is critical for clinical trial enrollment. In the era of amyloid-lowering therapies, there is a need to identify individuals likely to have amyloid to enrich recruitment and lower costs related to amyloid PET. In addition, a subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but to date there is no cognitive assessment or screening method that can detect these individuals in the absence of expensive biomarkers.
View Article and Find Full Text PDFBackground: Semantic cognition refers to our ability to manipulate and generalize knowledge and plays a critical role in communication and daily activities. Therefore, impairments in semantic cognition can have a severe impact on quality of life (e.g.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland, UK.
Background: To date, all computerised perivascular spaces (PVS) quantification methods require case-wise, imaging modality, or study-specific parameter adjustments, and suffer from generalisability problems in clinical settings, and misdetection of other cerebral small vessel disease (CSVD) markers. We propose a deep learning-based PVS detection method to overcome these issues. We compare our proposal on magnetic resonance imaging data of CSVD participants against the performance of the Frangi filter.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!